BR112021022789A2 - Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a - Google Patents

Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a

Info

Publication number
BR112021022789A2
BR112021022789A2 BR112021022789A BR112021022789A BR112021022789A2 BR 112021022789 A2 BR112021022789 A2 BR 112021022789A2 BR 112021022789 A BR112021022789 A BR 112021022789A BR 112021022789 A BR112021022789 A BR 112021022789A BR 112021022789 A2 BR112021022789 A2 BR 112021022789A2
Authority
BR
Brazil
Prior art keywords
tl1a
systems
methods
devices
selecting patients
Prior art date
Application number
BR112021022789A
Other languages
English (en)
Portuguese (pt)
Inventor
Dalin Li
P Mcgovern Dermot
Janine Bilsborough
Laurens Kruidenier
Mahyar Sabripour
Original Assignee
Cedars Sinai Medical Center
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Prometheus Biosciences Inc filed Critical Cedars Sinai Medical Center
Publication of BR112021022789A2 publication Critical patent/BR112021022789A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021022789A 2019-05-14 2020-05-13 Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a BR112021022789A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847798P 2019-05-14 2019-05-14
PCT/US2020/032679 WO2020232125A1 (en) 2019-05-14 2020-05-13 Tl1a patient selection methods, systems, and devices

Publications (1)

Publication Number Publication Date
BR112021022789A2 true BR112021022789A2 (pt) 2022-04-19

Family

ID=73228513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022789A BR112021022789A2 (pt) 2019-05-14 2020-05-13 Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a

Country Status (12)

Country Link
US (5) US20200362025A1 (https=)
EP (1) EP3969621A4 (https=)
JP (2) JP2022533956A (https=)
KR (1) KR20220088529A (https=)
CN (1) CN114375339A (https=)
AU (1) AU2020275413A1 (https=)
BR (1) BR112021022789A2 (https=)
CA (1) CA3140029A1 (https=)
IL (1) IL288017A (https=)
MX (1) MX2021013974A (https=)
TW (1) TW202108614A (https=)
WO (1) WO2020232125A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
CA3197828A1 (en) * 2020-11-13 2022-05-19 Laurens Kruidenier Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4263585A4 (en) * 2020-12-21 2024-11-27 Cedars-Sinai Medical Center THERAPEUTIC COMPOSITIONS OF TL1A AND METHODS OF TREATMENT USING THEM
CA3207818A1 (en) * 2021-02-18 2022-08-25 Allison LUO Anti-tl1a antibody compositions and methods of treatment in the lung
WO2022232253A1 (en) * 2021-04-28 2022-11-03 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a
CA3262839A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
EP4637819A1 (en) * 2022-12-22 2025-10-29 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
EP4665395A1 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the liver
KR20260013470A (ko) * 2023-05-17 2026-01-28 제넨테크, 인크. 항-tl1a 항체 치료 방법
EP4719473A1 (en) * 2023-05-26 2026-04-08 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases by targeting tl1a
CN121794295A (zh) * 2023-06-21 2026-04-03 派拉冈医疗公司 Tl1a抗体组合物及使用方法
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
WO2026072983A1 (en) 2024-09-27 2026-04-02 Genentech, Inc. Methods for treatment of atopic dermatitis with an anti-tl1a antibody
WO2026072993A1 (en) 2024-09-27 2026-04-02 Genentech, Inc. Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody
CN120089402A (zh) * 2025-03-10 2025-06-03 广州敏特生物技术有限公司 一种结合抗nf155抗体检测和酶联免疫吸附试验的检测方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5523302A (en) 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US7531310B2 (en) 2000-11-17 2009-05-12 Bristol-Myers Squibb Company Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11
JP2005504510A (ja) 2000-11-17 2005-02-17 ブリストル−マイヤーズ　スクイブ　カンパニー 心臓で高度に発現される新規なヒトｇタンパク質共役レセプター、ｈｇｐｒｂｍｙ１１およびその変異体
US20030224400A1 (en) 2000-11-17 2003-12-04 Barber Lauren E. Novel human G-protein coupled receptor, HGPRBMY11, and variants thereof
SE0004928D0 (sv) 2000-12-29 2000-12-29 Apbiotech Ab A method for the manufacturing of porous material
WO2002059264A2 (en) 2000-12-29 2002-08-01 Bio-Technology General Corp. Specific human antibodies for selective cancer therapy
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
ATE518011T1 (de) 2006-04-07 2011-08-15 Hitachi Chemical Co Ltd Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008106451A2 (en) 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008107389A1 (en) 2007-03-02 2008-09-12 Universite De Liege A method for determining the genotype at the crohn's disease locus
US9305137B1 (en) 2007-05-18 2016-04-05 Cedars-Sinai Medical Center Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
US20150376707A1 (en) 2007-05-18 2015-12-31 Cedars-Sinai Medical Center Methods of diagnosing and treating inflammatory bowel disease
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
SI2257643T1 (sl) 2008-02-19 2018-12-31 The Children's Hospital Of Philadelphia Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni
CN102171365B (zh) 2008-08-25 2014-01-29 森托科尔奥索生物科技公司 用于溃疡性结肠炎和相关疾病的抗tnf治疗的生物标记物
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
CA2758531C (en) 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
CN102639710A (zh) 2009-07-20 2012-08-15 基因泰克公司 克罗恩病的基因表达标记
US8301232B2 (en) 2010-06-08 2012-10-30 Alivecor, Inc. Wireless, ultrasonic personal health monitoring system
JP2013540995A (ja) 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 疾患に対する循環バイオマーカー
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
KR102035877B1 (ko) 2011-11-14 2019-10-23 알파시그마 에스.피.에이. 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
EA201591153A1 (ru) 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
WO2014186750A2 (en) 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
SG11201509371XA (en) 2013-05-24 2015-12-30 Nestec Sa Pathway specific markers for diagnosing irritable bowel syndrome
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
US10349888B2 (en) 2013-10-08 2019-07-16 Carlos Federico Muniz Wearable electroencephalography device and methods of use thereof
MX388027B (es) * 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
WO2022187196A1 (en) 2021-03-02 2022-09-09 Dermtech, Inc. Predicting therapeutic response
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
US10261098B2 (en) 2014-08-18 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
WO2016040879A1 (en) 2014-09-12 2016-03-17 The Board Of Trustees Of The Leland Stanford Junior University Physical examination method and apparatus
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
US10477354B2 (en) 2015-02-20 2019-11-12 Mc10, Inc. Automated detection and configuration of wearable devices based on on-body status, location, and/or orientation
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US10732092B2 (en) 2015-12-22 2020-08-04 University Of Maryland, College Park Analysis of single cell mechanical phenotyping for metastatic detection
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
WO2017189846A1 (en) 2016-04-27 2017-11-02 Thaddeus Stappenbeck Methods for prognosing crohn's disease comprising human defensin 5 (hd5)
KR102481305B1 (ko) 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
US10458996B1 (en) 2016-05-20 2019-10-29 Beth Israel Deaconess Medical Center, Inc. Methods for determining clinical response to TNF-alpha and/or JAK inhibitors in subjects with inflammatory diseases
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN110446508A (zh) 2016-12-29 2019-11-12 泰普治疗公司 用于治疗医疗植入物部位的方法和系统
US20190070166A1 (en) 2017-09-02 2019-03-07 Richard Postrel Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
US10961581B2 (en) 2017-03-22 2021-03-30 Board Of Regents, The University Of Texas System Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932)
US10635787B2 (en) 2017-04-19 2020-04-28 International Business Machines Corporation Analysis of output files
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
EP3654993A4 (en) 2017-07-17 2021-08-25 The Broad Institute, Inc. CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
US20220112625A1 (en) 2017-09-02 2022-04-14 Richard Postrel Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses
EP3695229A1 (en) 2017-10-10 2020-08-19 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
WO2019079647A2 (en) 2017-10-18 2019-04-25 Wuxi Nextcode Genomics Usa, Inc. IA STATISTICS FOR DEEP LEARNING AND PROBABILISTIC PROGRAMMING, ADVANCED, IN BIOSCIENCES
US12599656B2 (en) 2018-03-12 2026-04-14 Stemcell Technologies Canada Inc. Methods for treating HPV-associated diseases
EP3778328B1 (en) 2018-03-27 2023-05-17 Nissan Motor Co., Ltd. Method and device for controlling automatic driving vehicle
CA3097874A1 (en) 2018-04-24 2019-10-31 Cedars-Sinai Medical Center Methods and systems for characterizing severe crohn's disease
JP7332627B2 (ja) 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体
TW202014217A (zh) 2018-04-27 2020-04-16 美國錫安山醫學中心 標靶gpr35以治療發炎性腸病症的組合物及方法
ES2962715T3 (es) 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
CA3105464A1 (en) 2018-07-06 2020-01-09 Cedars-Sinai Medical Center Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
WO2020081186A1 (en) 2018-10-15 2020-04-23 Cedars-Sinai Medical Center Methods of treating and diagnosing inflammatory bowel disease
WO2020082090A1 (en) 2018-10-19 2020-04-23 The Regents Of The University Of Michigan Method for monitoring autoimmune disease
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
CA3121167A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
CA3124970A1 (en) 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
KR20210130168A (ko) 2019-02-08 2021-10-29 세다르스-신나이 메디칼 센터 Il18r1을 표적화하는 염증성 질환의 치료를 위한 방법, 시스템 및 키트
WO2020163713A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
CA3131701A1 (en) 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
WO2020242976A1 (en) 2019-05-24 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of polygenic diseases and phenotypes from genetic variation
US20210018490A1 (en) 2019-07-19 2021-01-21 The Regents Of The University Of Michigan Compositions and methods for individualized characterization of non-ige mediated food allergies
WO2021081365A1 (en) 2019-10-24 2021-04-29 Prometheus Biosciences, Inc. Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
EP4162067A4 (en) 2020-06-03 2024-07-10 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR MEASURING THE RECURRENCE OF POSTOPERATIVE DISEASES
EP4162076A4 (en) 2020-06-03 2024-10-02 Cedars-Sinai Medical Center TREATMENTS FOR A SUBPOPULATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
CN116322762A (zh) 2020-06-26 2023-06-23 辉瑞公司 用tl1a抗体治疗炎症性肠病的方法
WO2022087313A1 (en) 2020-10-22 2022-04-28 Progenity, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
US20240018592A1 (en) 2020-10-26 2024-01-18 Technion Research & Development Foundation Limited Methods of assessing the therapeutic activity of agents for the treatment of immune disorders
CA3197828A1 (en) 2020-11-13 2022-05-19 Laurens Kruidenier Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4256086A4 (en) 2020-12-01 2025-01-15 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES
EP4263585A4 (en) 2020-12-21 2024-11-27 Cedars-Sinai Medical Center THERAPEUTIC COMPOSITIONS OF TL1A AND METHODS OF TREATMENT USING THEM
CA3207818A1 (en) 2021-02-18 2022-08-25 Allison LUO Anti-tl1a antibody compositions and methods of treatment in the lung
AU2022223420A1 (en) 2021-02-18 2023-09-21 Cedars-Sinai Medical Center Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
MX2023010694A (es) 2021-03-12 2023-11-23 Janssen Biotech Inc Métodos para predecir la respuesta al tratamiento en la colitis ulcerosa.
WO2022232253A1 (en) 2021-04-28 2022-11-03 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a

Also Published As

Publication number Publication date
JP2022533956A (ja) 2022-07-27
IL288017A (en) 2022-01-01
US20230272061A1 (en) 2023-08-31
US20250340627A1 (en) 2025-11-06
JP2025092795A (ja) 2025-06-20
WO2020232125A1 (en) 2020-11-19
US20230018729A1 (en) 2023-01-19
US12391752B2 (en) 2025-08-19
TW202108614A (zh) 2021-03-01
AU2020275413A1 (en) 2021-12-23
KR20220088529A (ko) 2022-06-27
US20210101988A1 (en) 2021-04-08
EP3969621A4 (en) 2023-01-25
US12215147B2 (en) 2025-02-04
CA3140029A1 (en) 2020-11-19
CN114375339A (zh) 2022-04-19
US11136386B2 (en) 2021-10-05
US20200362025A1 (en) 2020-11-19
MX2021013974A (es) 2022-02-10
EP3969621A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112018068906A2 (pt) composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
ECSP18081954A (es) Detección de infección microbiana en heridas
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
GT201700246A (es) Métodos y kits para tratar la depresión
MX387283B (es) Tratamiento del cancer con tg02.
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
BR112015024300A2 (pt) sistema de planejamento de terapia para tratamento de um alvo interno de um paciente, método de aplicação de terapia para tratamento de um alvo interno de um paciente, um ou mais processadores programados para controlar o tratamento de uma parte interna de um paciente, mídia legível por computador não temporária, e sistema de aplicação de terapia para tratamento de um alvo interno de um paciente
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
BR112016008694A2 (pt) Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
BR112023009172A2 (pt) Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a
MX2020009154A (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
MX388914B (es) Un inhibidor de punto de control y una celula de mycobacterium para su utilizacion en el tratamiento contra cancer.
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
BR112014020233A2 (pt) seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
BR112021020525A2 (pt) Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112017023170A2 (pt) dispositivo de banho medicinal e seu uso
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
BR112019009495A2 (pt) métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes